The prevalence of obesity and PCOS was highest in women using GLP-1 receptor agonists; chronic hypertension, cardiovascular disease, and use of antihypertensive and lipid-modifying agents were highest in SGLT2 inhibitor users. This evidence concerns the gene GLP1R and cardiovascular disorder.